Medical Device Testing Services Market: Market Size & Forecast 2026

Medical device testing services encompass biocompatibility evaluation, sterility and microbiology testing, electrical safety, performance verification, and regulatory submission support provided by third-party labs and certification bodies. The market is concentrated in regions with strong medical device manufacturing bases and mature regulatory frameworks, notably North America and Western Europe, while Asia-Pacific is expanding rapidly as both production and clinical trial activity shift eastward. Estimates for 2025 vary by source from roughly USD 9.5 billion to USD 14.0 billion, and forward CAGRs range from about 4.8% to 9.5% depending on scope and methodology.

• •2025 global market valuation: approximately USD 11.36 billion, with a forecast CAGR near 7.96%.
• •Core service lines include biocompatibility, sterility, EMC/electrical safety, performance, and materials testing.
• •Most projections place 2030 value between USD 15 billion and USD 25 billion depending on growth assumptions.

Tightening regulations in major markets such as the EU MDR, US FDA Quality Management System Rule, and emerging frameworks in Asia are forcing manufacturers to invest in more comprehensive testing and documentation. Rising device complexity, including connected, software-driven, and AI-enabled devices, is also expanding the scope and cost of required testing programs. At the same time, growing R&D spending and a strong pipeline of innovative devices across diagnostics, cardiovascular, orthopedic, and digital health categories are sustaining demand for outsourced services.

• •Regulatory tightening under EU MDR, IVDR, and FDA reforms increases testing volume per device.
• •Software as a Medical Device (SaMD) and connected devices require cybersecurity and interoperability testing.
• •Outsourcing penetration is rising as OEMs prioritize core development over in-house lab capacity.

By service type, the market spans biocompatibility, microbiology and sterility, performance testing, electrical and EMC testing, and clinical or usability evaluation, with biocompatibility and microbiology typically representing the largest revenue shares. By device type, segments include diagnostic imaging, cardiovascular, orthopedic, IVD, surgical instruments, and digital health devices. Geographically, North America leads in revenue thanks to a dense base of device makers and FDA-driven demand, Europe follows closely, and Asia-Pacific is the fastest-growing region as China, India, and Southeast Asia expand domestic manufacturing and regulatory capacity.

• •North America holds the largest revenue share, with US-only spend estimated near USD 2.7 billion in 2025.
• •Asia-Pacific is the fastest-growing region, supported by manufacturing relocation and harmonized regulations.
• •In vitro diagnostic (IVD) devices represent a high-growth sub-segment under tightening IVDR requirements.

What are the recent trends and outlook?

Going forward, demand is expected to remain structurally strong as device portfolios grow more complex and regulatory scrutiny continues to intensify across major and emerging markets. AI-enabled devices, combination products, and increased cybersecurity and usability requirements are widening the testing scope per product, while harmonization initiatives may gradually reduce redundant testing across regions. Overall, the market is positioned for sustained mid-to-high single-digit annual growth through the decade, with the most optimistic scenarios pointing toward a USD 20 billion-plus market by the early 2030s.

• •AI/ML-enabled and software-driven devices are creating new test categories such as algorithmic validation and post-market surveillance analytics.
• •Capacity expansion in Asia-Pacific is a key strategic priority for global TIC providers.
• •Long-term outlook supports continued mid-to-high single-digit CAGR, with 2034 projections ranging from roughly USD 20 billion to over USD 25 billion.